Targeted therapies: How personal should we go?

Miriam Martini, Loredana Vecchione, Salvatore Siena, Sabine Tejpar, Alberto Bardelli

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Despite the development of drugs inhibiting the oncogenic proteins that cancer cells are dependent on, attempts to match targeted therapies to the genetic makeup of individual tumors is proving more difficult than expected. Until now, the paradigm has been a binary correlation between a mutated cancer gene and response to a given therapy. However, recent evidence indicates that different genetic alterations, such as mutations in different codons of a cancer gene, might be related to distinct sensitivity to targeted therapies. An example is the divergent effect that individual EGFR, PIK3CA and KRAS mutations might have on response or resistance to tailored drugs. Furthermore, the idea that the presence of a specific mutation translates into sensitivity or resistance to a particular drug is likely too simplistic, since it does not capture the complexity of the signaling pathways in an individual cancer. Only the overall genetic milieu (alterations in upstream and/or parallel pathways) ultimately determines the response of individual tumors to therapy. We have critically analyzed data supporting the genetic, biological and biochemical differences of individual mutations within a single cancer gene. The role of cancer mutations as predictors of sensitivity and resistance to targeted therapies is discussed, together with the implications for the 'personalized' treatment of cancer patients.

Original languageEnglish
Pages (from-to)87-97
Number of pages11
JournalNature Reviews Clinical Oncology
Volume9
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Neoplasm Genes
Mutation
Neoplasms
Therapeutics
Pharmaceutical Preparations
Individuality
Codon
Genetic Therapy
Molecular Biology
Proteins

ASJC Scopus subject areas

  • Oncology

Cite this

Targeted therapies : How personal should we go? / Martini, Miriam; Vecchione, Loredana; Siena, Salvatore; Tejpar, Sabine; Bardelli, Alberto.

In: Nature Reviews Clinical Oncology, Vol. 9, No. 2, 02.2012, p. 87-97.

Research output: Contribution to journalArticle

Martini, Miriam ; Vecchione, Loredana ; Siena, Salvatore ; Tejpar, Sabine ; Bardelli, Alberto. / Targeted therapies : How personal should we go?. In: Nature Reviews Clinical Oncology. 2012 ; Vol. 9, No. 2. pp. 87-97.
@article{acf0cd5b670647158d706222ae50605f,
title = "Targeted therapies: How personal should we go?",
abstract = "Despite the development of drugs inhibiting the oncogenic proteins that cancer cells are dependent on, attempts to match targeted therapies to the genetic makeup of individual tumors is proving more difficult than expected. Until now, the paradigm has been a binary correlation between a mutated cancer gene and response to a given therapy. However, recent evidence indicates that different genetic alterations, such as mutations in different codons of a cancer gene, might be related to distinct sensitivity to targeted therapies. An example is the divergent effect that individual EGFR, PIK3CA and KRAS mutations might have on response or resistance to tailored drugs. Furthermore, the idea that the presence of a specific mutation translates into sensitivity or resistance to a particular drug is likely too simplistic, since it does not capture the complexity of the signaling pathways in an individual cancer. Only the overall genetic milieu (alterations in upstream and/or parallel pathways) ultimately determines the response of individual tumors to therapy. We have critically analyzed data supporting the genetic, biological and biochemical differences of individual mutations within a single cancer gene. The role of cancer mutations as predictors of sensitivity and resistance to targeted therapies is discussed, together with the implications for the 'personalized' treatment of cancer patients.",
author = "Miriam Martini and Loredana Vecchione and Salvatore Siena and Sabine Tejpar and Alberto Bardelli",
year = "2012",
month = "2",
doi = "10.1038/nrclinonc.2011.164",
language = "English",
volume = "9",
pages = "87--97",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Targeted therapies

T2 - How personal should we go?

AU - Martini, Miriam

AU - Vecchione, Loredana

AU - Siena, Salvatore

AU - Tejpar, Sabine

AU - Bardelli, Alberto

PY - 2012/2

Y1 - 2012/2

N2 - Despite the development of drugs inhibiting the oncogenic proteins that cancer cells are dependent on, attempts to match targeted therapies to the genetic makeup of individual tumors is proving more difficult than expected. Until now, the paradigm has been a binary correlation between a mutated cancer gene and response to a given therapy. However, recent evidence indicates that different genetic alterations, such as mutations in different codons of a cancer gene, might be related to distinct sensitivity to targeted therapies. An example is the divergent effect that individual EGFR, PIK3CA and KRAS mutations might have on response or resistance to tailored drugs. Furthermore, the idea that the presence of a specific mutation translates into sensitivity or resistance to a particular drug is likely too simplistic, since it does not capture the complexity of the signaling pathways in an individual cancer. Only the overall genetic milieu (alterations in upstream and/or parallel pathways) ultimately determines the response of individual tumors to therapy. We have critically analyzed data supporting the genetic, biological and biochemical differences of individual mutations within a single cancer gene. The role of cancer mutations as predictors of sensitivity and resistance to targeted therapies is discussed, together with the implications for the 'personalized' treatment of cancer patients.

AB - Despite the development of drugs inhibiting the oncogenic proteins that cancer cells are dependent on, attempts to match targeted therapies to the genetic makeup of individual tumors is proving more difficult than expected. Until now, the paradigm has been a binary correlation between a mutated cancer gene and response to a given therapy. However, recent evidence indicates that different genetic alterations, such as mutations in different codons of a cancer gene, might be related to distinct sensitivity to targeted therapies. An example is the divergent effect that individual EGFR, PIK3CA and KRAS mutations might have on response or resistance to tailored drugs. Furthermore, the idea that the presence of a specific mutation translates into sensitivity or resistance to a particular drug is likely too simplistic, since it does not capture the complexity of the signaling pathways in an individual cancer. Only the overall genetic milieu (alterations in upstream and/or parallel pathways) ultimately determines the response of individual tumors to therapy. We have critically analyzed data supporting the genetic, biological and biochemical differences of individual mutations within a single cancer gene. The role of cancer mutations as predictors of sensitivity and resistance to targeted therapies is discussed, together with the implications for the 'personalized' treatment of cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84856597110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856597110&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2011.164

DO - 10.1038/nrclinonc.2011.164

M3 - Article

C2 - 22083042

AN - SCOPUS:84856597110

VL - 9

SP - 87

EP - 97

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 2

ER -